Alpha Tau Medical Ltd.
DRTS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.96 | 0.34 | 0.29 | -0.07 |
| FCF Yield | -10.16% | -11.70% | -12.27% | -3.70% |
| EV / EBITDA | -7.12 | -7.45 | -6.15 | -32.44 |
| Quality | ||||
| ROIC | -45.32% | 34.86% | -27.61% | -36.48% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.62 | 0.62 | 0.71 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 9.60% | 1.71% | -68.15% | -33.77% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | -0.02 | 0.02 | -2.33 |
| Interest Coverage | -104.77 | 914.87 | -18.17 | -1.04 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -56.53 | 0.00 | -0.09 |
| Cash Conversion Cycle | -1,169.52 | -878.51 | -530.54 | -4,408.22 |